Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed multifunctional nanofiber wound dressings that significantly reduced bacteria and promoted healing in a mouse wound model by incorporating antibacterial and growth-promoting agents.

In this study, the release rate of Finasteride from Eudragit matrix tablets was found to be significantly influenced by the drug/Eudragit ratio and polymer viscosity, with formulation F9 being the most effective.

This study found that bupropion SR may improve symptoms in female trichotillomania patients who did not respond to SSRIs, with benefits maintained through a 16-month follow-up.

In this study, a chitosan-based minoxidil nanogel was developed and optimized for better scalp retention and targeted follicular delivery, showing sustained drug release over 48 hours and improved drug deposition compared to conventional minoxidil solutions.

This study investigated improving Finasteride's water solubility using trimethyl-β-cyclodextrin (TM-β-CD) and β-cyclodextrin (β-CD) as carriers, finding that β-CD improved Fin's cumulative release, while TM-β-CD enhanced its solubility, with computational data supporting these outcomes.

In this study, researchers developed a new microneedle patch delivery system for minoxidil, which enhanced its controlled release and improved hair growth in mice, potentially offering better treatment outcomes for androgenetic alopecia.

This study suggests that the key mechanism of stress-related hair loss involves CRH-induced PTEN loss, which reduces autophagy and increases apoptosis in dermal papilla cells, highlighting potential therapeutic targets like PTEN activation or autophagy enhancement.

This study developed a NIR light-triggered NO-releasing hydrogel that promotes angiogenesis, repairs damaged dermal papilla cells, reduces inflammation, and improves the nutrient supply and follicular environment in animal models, offering a promising treatment strategy for androgenic alopecia.

Ganoderma lucidum extract may help treat stress-related hair loss.

This study found that tildacerfont treatment in males with congenital adrenal hyperplasia reduced androgen levels and improved markers of testicular function, suggesting potential benefits for male reproductive health.

The study found that cyproterone acetate could be released over 15 days using coconut oil mixed with certain wax inhibitors, though further safety studies are needed.

This study concluded that macrophage iron retention due to Ferroportin inactivation hinders skin wound healing but does not affect liver damage or fibrogenesis in a mouse model.

This study investigates the potential role of the corticotropin-releasing hormone system in the pathogenesis of lichen planus but does not report new clinical results, emphasizing the need for further exploration.

This study reports that controlled release PRP therapy using dalteparin and protamine micro-particles may be effective for hair growth and skin rejuvenation in women.

This study suggests that novel lipid nanoparticle formulations may be suitable for delivering anti-alopecia compounds like minoxidil and finasteride, although their skin penetration was limited.

This study found that poly(propylene carbonate maleate) microspheres can successfully prolong finasteride release over 42 days, showing potential for long-term sustained drug delivery.

In this study, oral testosterone administered three times daily normalized serum testosterone levels in men with experimentally induced hypogonadism over nine days and significantly reduced SHBG.

Finasteride sustained-release tablets are stable.

This study outlines a hair regrowth treatment targeting hair follicle stem cells, 5-alpha reductase pathway, and microinflammation using PDGF and VEGF, but reports no clinical results.

This study found that normal human epidermis expresses TSH and may be an indirect target of TSH signaling, with expression regulated by endocrine controls of the hypothalamic-pituitary-thyroid axis.

This study found that long-term GnRH agonist administration in premenopausal women with polycystic ovarian disease resulted in persistent suppression of ovarian steroid secretion, while adrenal steroid levels remained unchanged.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This study found that nafarelin treatment significantly reduced androgen levels and improved hirsutism symptoms in women, suggesting it may be useful for managing this condition.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that women with PCOS who have an exaggerated 17-hydroxyprogesterone response to buserelin exhibit more severe hyperandrogenemia, increased insulin secretion, and reduced insulin sensitivity.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This study established a mouse model for Cushing's syndrome due to a specific Crh mutation, which may help explore the effects of glucocorticoid excess and evaluate treatments for corticosteroid-induced osteoporosis.

This case study details a 57-year-old woman with symptoms of androgen excess, including rapid hair growth and temporal balding, alongside abnormal testosterone levels and a history of chronic renal failure.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.